PPARA and urinary bladder carcinoma: Based on our analysis of differentially expressed transcription factors identified through the TCGA bladder study, and our characterization of bladder cancer cell lines showing similar transcription factor expression patterns (Fig. 3), we chose to examine the impact of GATA3 and FOXA1 expression on the regulation of markers of luminal and basal bladder cancer in the presence and absence of the PPARɣ agonist rosiglitazone.